Literature DB >> 22015352

Efficacy of improgan, a non-opioid analgesic, in neuropathic pain.

Phillip J Albrecht1, Julia W Nalwalk, Lindsay B Hough.   

Abstract

Improgan, a non-opioid analgesic, is known to act in the rodent brain stem to produce highly effective antinociception in several acute pain tests. However, improgan has not been studied in any models of chronic pain. To assess the efficacy of improgan in an animal model of neuropathic pain, the effects of this drug were studied on mechanical allodynia following unilateral spinal nerve ligation (SNL) in rats. Intracerebroventricular (icv) improgan (40-80 μg) produced complete, reversible, dose-dependent attenuation of hind paw mechanical allodynia for up to 1h after administration, with no noticeable behavioral or motor side effects. Intracerebral (ic) microinjections of improgan (5-30 μg) into the rostral ventromedial medulla (RVM) also reversed the allodynia, showing this brain area to be an important site for improgan's action. The recently-demonstrated suppression of RVM ON-cell activity by improgan may account for the presently-observed anti-allodynic activity. The present findings suggest that brain-penetrating, improgan-like drugs developed for human use could be effective medications for the treatment of neuropathic pain. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015352      PMCID: PMC3242473          DOI: 10.1016/j.brainres.2011.10.002

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  27 in total

1.  Activation of brain stem nuclei by improgan, a non-opioid analgesic.

Authors:  J W Nalwalk; K Svokos; O Taraschenko; R Leurs; H Timmerman; L B Hough
Journal:  Brain Res       Date:  2004-09-24       Impact factor: 3.252

2.  Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic.

Authors:  Lindsay B Hough; Iwan J P de Esch; Elwin Janssen; James Phillips; Konstantina Svokos; Brian Kern; Jennifer Trachler; Mary E Abood; Rob Leurs; Julia W Nalwalk
Journal:  Neuropharmacology       Date:  2006-06-23       Impact factor: 5.250

Review 3.  Mechanisms of neuropathic pain.

Authors:  James N Campbell; Richard A Meyer
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

4.  Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic.

Authors:  Lindsay B Hough; Julia W Nalwalk; Qun Lu; Zhixing Shan; Konstantina Svokos; Mark P Wentland; M José Montero
Journal:  Eur J Pharmacol       Date:  2005-10-10       Impact factor: 4.432

Review 5.  Mechanisms of neuropathic pain and their implications for the design of clinical trials.

Authors:  Michael C Rowbotham
Journal:  Neurology       Date:  2005-12-29       Impact factor: 9.910

6.  Absence of 5-HT3 and cholinergic mechanisms in improgan antinociception.

Authors:  J W Nalwalk; K Svokos; R Leurs; L B Hough
Journal:  Pharmacol Biochem Behav       Date:  2005-03       Impact factor: 3.533

7.  An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat.

Authors:  Sun Ho Kim; Jin Mo Chung
Journal:  Pain       Date:  1992-09       Impact factor: 6.961

8.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

9.  Effects of cimetidine-like drugs on recombinant GABAA receptors.

Authors:  Keri E Cannon; Mark W Fleck; Lindsay B Hough
Journal:  Life Sci       Date:  2004-10-08       Impact factor: 5.037

10.  Significance of cannabinoid CB1 receptors in improgan antinociception.

Authors:  Neal C Gehani; Julia W Nalwalk; Raj K Razdan; Billy R Martin; Xufung Sun; Mark Wentland; Mary E Abood; Lindsay B Hough
Journal:  J Pain       Date:  2007-07-23       Impact factor: 5.820

View more
  1 in total

1.  Antinociceptive activity of CC44, a biotinylated improgan congener.

Authors:  Paul Hoerbelt; Julia W Nalwalk; James G Phillips; Mark P Wentland; Zhixing Shan; Lindsay B Hough
Journal:  Eur J Pharmacol       Date:  2013-07-05       Impact factor: 4.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.